Mersana Therapeutics, Inc. (MRSN): Price and Financial Metrics


Mersana Therapeutics, Inc. (MRSN)

Today's Latest Price: $23.87 USD

0.52 (2.23%)

Updated Nov 23 6:55pm

Add MRSN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

MRSN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for MRSN is 0 -- better than just 9% of US stocks.
  • With a price/sales ratio of 1,859.78, Mersana Therapeutics Inc has a higher such ratio than 99.59% of stocks in our set.
  • As for revenue growth, note that MRSN's revenue has grown -98.01% over the past 12 months; that beats the revenue growth of merely 0.76% of US companies in our set.
  • Stocks that are quantitatively similar to MRSN, based on their financial statements, market capitalization, and price volatility, are GERN, CBMG, CRNX, SPCE, and ARNA.
  • Visit MRSN's SEC page to see the company's official filings. To visit the company's web site, go to www.mersana.com.

MRSN Stock Price Chart Interactive Chart >

Price chart for MRSN

MRSN Price/Volume Stats

Current price $23.87 52-week high $26.64
Prev. close $23.35 52-week low $3.20
Day low $23.38 Volume 666,300
Day high $24.23 Avg. volume 1,172,248
50-day MA $20.32 Dividend yield N/A
200-day MA $15.86 Market Cap 1.64B

Mersana Therapeutics, Inc. (MRSN) Company Bio


Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patients’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.


MRSN Latest News Stream


Event/Time News Detail
Loading, please wait...

MRSN Latest Social Stream


Loading social stream, please wait...

View Full MRSN Social Stream

Latest MRSN News From Around the Web

Below are the latest news stories about Mersana Therapeutics Inc that investors may wish to consider to help them evaluate MRSN as an investment opportunity.

Mersana Therapeutics EPS misses by $0.03, beats on revenue

Mersana Therapeutics (MRSN): Q2 GAAP EPS of -$0.33 misses by $0.03.Revenue of $0.8M (+300.0% Y/Y) beats by $0.62M.Press Release...

Seeking Alpha | August 7, 2020

Mersana Therapeutics' (MRSN) CEO Anna Protopapas on Q2 2020 Results - Earnings Call Transcript

Mersana Therapeutics, Inc. (MRSN) Q2 2020 Earnings Conference Call August 7, 2020 8:00 AM ET Company Participants Sarah Carmody – Executive Director, Investor Relations and Corporate Communications Anna Protopapas – President and Chief Executive Officer Tim Lowinger – Chief Science and Technology Officer Brian DeSchuytner – Senior Vice President Finance...

SA Transcripts on Seeking Alpha | August 7, 2020

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will host a conference call and webcast on Friday, August 7, 2020 at 8:00 a.m. ET to report financial results for the second quarter ended June 30, 2020 and provide business updates.  To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 1081289. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com. About Mersana Therapeutics Mersana Therapeutics is a cl...

Yahoo | July 31, 2020

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced the publication of data in the journal Nature Communications that support the company’s proprietary approach to precisely upregulate protein expression using TANGO (Targeted Augmentation of Nuclear Gene Output) antisense oligonucleotides (ASOs).

Yahoo | July 9, 2020

Here is What Hedge Funds Think About Stoke Therapeutics, Inc. (STOK)

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

Yahoo | July 8, 2020

Read More 'MRSN' Stories Here

MRSN Price Returns

1-mo 29.17%
3-mo 30.44%
6-mo 21.23%
1-year 566.76%
3-year 25.96%
5-year N/A
YTD 316.58%
2019 40.44%
2018 -75.17%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.943 seconds.